Terrie Curran Sells 19,109 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of Phathom Pharmaceuticals stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the transaction, the insider now directly owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. The trade was a 5.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phathom Pharmaceuticals Price Performance

NASDAQ:PHAT opened at $6.90 on Friday. Phathom Pharmaceuticals, Inc. has a 1-year low of $6.07 and a 1-year high of $19.71. The business’s 50-day moving average price is $8.04 and its two-hundred day moving average price is $12.50.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to analyst estimates of $12.54 million. During the same period in the previous year, the company posted ($0.76) EPS. Analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of hedge funds have recently modified their holdings of PHAT. Huntington National Bank raised its position in shares of Phathom Pharmaceuticals by 62.2% during the third quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after purchasing an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after buying an additional 722 shares in the last quarter. US Bancorp DE grew its holdings in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after buying an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Phathom Pharmaceuticals by 10.6% during the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Phathom Pharmaceuticals during the third quarter worth about $197,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.